From Standard of Care to Emerging Innovations: Navigating the Evolution of Pharmacological Treatment of Gestational Diabetes

Abstract

The incidence of gestational diabetes mellitus (GDM) continues to increase in the United States and globally. While the first-line treatment of GDM remains diet and exercise, 30% of patients with GDM will require pharmacotherapy. However, many controversies remain over the specific glycemic threshold values at which pharmacotherapy should be started, how intensified the therapy should be, and whether oral agents are effective in GDM and remain safe for long-term offspring health. This review will summarize recently completed and ongoing trials focused on GDM pharmacotherapy, including those examining different glycemic thresholds to initiate therapy and treatment intensity.

Key Points

• The incidence of GDM continues to increase in the United States and globally.

• While the first-line treatment of GDM remains diet, 30% of patients require pharmacotherapy.

• Controversies remain over the specific glycemic threshold values at which pharmacotherapy is needed.

• Another controversy is how tightly to control GDM.

• Additional controversies are the safety of metformin and incretins in terms of offspring's long-term health.

Keywords

gestational diabetes - pharmacologic treatment - insulin - metformin - incretins

Each author has indicated that they have met the journal's requirements for authorship.

Publikationsverlauf

Eingereicht: 15. April 2024

Angenommen: 27. August 2024

Artikel online veröffentlicht:
27. September 2024

• References

• 1 Abouzeid M, Versace VL, Janus ED. et al. A population-based observational study of diabetes during pregnancy in Victoria, Australia, 1999-2008. BMJ Open 2014; 4 (11) e005394
• 2 Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 2014; 103 (02) 176-185
• 3 Nethery E, Law MR, Kotaska A, Janssen PA, Hutcheon JA. The effect of changing screening practices and demographics on the incidence of gestational diabetes in British Columbia, 2005-2019. CMAJ 2023; 195 (11) E396-E403
• 4 Shah NS, Wang MC, Freaney PM. et al. Trends in gestational diabetes at first live birth by race and ethnicity in the US, 2011-2019. JAMA 2021; 326 (07) 660-669
• 5 Venkatesh KK, Lynch CD, Powe CE. et al. Risk of adverse pregnancy outcomes among pregnant individuals with gestational diabetes by race and ethnicity in the United States, 2014-2020. JAMA 2022; 327 (14) 1356-1367
• 6 Metzger BE, Lowe LP, Dyer AR. et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358 (19) 1991-2002
• 7 Pillay J, Donovan L, Guitard S. et al. Screening for gestational diabetes: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021; 326 (06) 539-562
• 8 Vohr BR, Boney CM. Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome?. J Matern Fetal Neonatal Med 2008; 21 (03) 149-157
• 9 Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep 2016; 16 (01) 7
• 10 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352 (24) 2477-2486
• 11 Landon MB, Spong CY, Thom E. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361 (14) 1339-1348
• 12 American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol 2018; 131 (02) e49-e64
• 13 Society of Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: [e-mail]. SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol 2018; 218 (05) B2-B4
• 14 Nicholson WK, Wilson LM, Witkop CT. et al. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. Evid Rep Technol Assess (Full Rep) 2008; (162) 1-96
• 15 Crowther CA, Samuel D, Hughes R, Tran T, Brown J, Alsweiler JM. TARGET Study Group. Tighter or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity: a stepped-wedge, cluster-randomised trial. PLoS Med 2022; 19 (09) e1004087
• 16 Langer O. Management of gestational diabetes: pharmacologic treatment options and glycemic control. Endocrinol Metab Clin North Am 2006; 35 (01) 53-78 , vi
• 17 Harrison RK, Cruz M, Wong A, Davitt C, Palatnik A. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth 2020; 20 (01) 773
• 18 Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD, Arrendondo F. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 1994; 170 (04) 1036-1046 , discussion 1046–1047
• 19 Wexler DJ, Powe CE, Barbour LA. et al. Research gaps in gestational diabetes mellitus: executive summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. Obstet Gynecol 2018; 132 (02) 496-505
• 20 Langer O. Pharmacological treatment of gestational diabetes mellitus: point/counterpoint. Am J Obstet Gynecol 2018; 218 (05) 490-499
• 21 Brown J, Grzeskowiak L, Williamson K, Downie MR, Crowther CA. Insulin for the treatment of women with gestational diabetes. Cochrane Database Syst Rev 2017; 11 (11) CD012037
• 22 American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47 (Suppl. 01) S282-S294
• 23 NICE. . Accessed on March 10, 2024 at: https://www.nice.org.uk/guidance/ng3/chapter/Recommendations#g%20estational-diabetes
• 24 Ivers NM, Jiang M, Alloo J. et al. Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes. Can Fam Physician 2019; 65 (01) 14-24
• 25 Davitt C, Flynn KE, Harrison RK, Pan A, Palatnik A. Current practices in gestational diabetes mellitus diagnosis and management in the United States: survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2021; 225 (02) 203-204
• 26 Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon M. Glycemic control in gestational diabetes mellitus–how tight is tight enough: small for gestational age versus large for gestational age?. Am J Obstet Gynecol 1989; 161 (03) 646-653
• 27 Langer O. Glycemic targets for the optimal treatment of GDM. Clin Obstet Gynecol 2013; 56 (04) 788-802
• 28 Caissutti C, Saccone G, Ciardulli A, Berghella V. Very tight vs. tight control: what should be the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy? Evidence from randomized controlled trials. Acta Obstet Gynecol Scand 2018; 97 (03) 235-247
• 29 Palatnik A, Saffian E, Flynn KE. et al. GAP (gestational diabetes and pharmacotherapy) - study protocol for a randomized controlled, two-arm, single-site trial. Contemp Clin Trials 2023; 131: 107237
• 30 Yogev Y, Ben-Haroush A, Chen R, Rosenn B, Hod M, Langer O. Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women. Am J Obstet Gynecol 2004; 191 (03) 949-953
• 31 Parretti E, Mecacci F, Papini M. et al. Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care 2001; 24 (08) 1319-1323
• 32 Siegmund T, Rad NT, Ritterath C, Siebert G, Henrich W, Buhling KJ. Longitudinal changes in the continuous glucose profile measured by the CGMS in healthy pregnant women and determination of cut-off values. Eur J Obstet Gynecol Reprod Biol 2008; 139 (01) 46-52
• 33 Cousins L, Rigg L, Hollingsworth D, Brink G, Aurand J, Yen SS. The 24-hour excursion and diurnal rhythm of glucose, insulin, and C-peptide in normal pregnancy. Am J Obstet Gynecol 1980; 136 (04) 483-488
• 34 Porter H, Lookinland S, Belfort MA. Evaluation of a new real-time blood continuous glucose monitoring system in pregnant women without gestational diabetes. A pilot study. J Perinat Neonatal Nurs 2004; 18 (02) 93-102
• 35 Metzger BE, Phelps RL, Freinkel N, Navickas IA. Effects of gestational diabetes on diurnal profiles of plasma glucose, lipids, and individual amino acids. Diabetes Care 1980; 3 (03) 402-409
• 36 Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged?. Diabetes Care 2011; 34 (07) 1660-1668
• 37 Lewis SB, Wallin JD, Kuzuya H. et al. Circadian variation of serum glucose, C-peptide immunoreactivity and free insulin normal and insulin-treated diabetic pregnant subjects. Diabetologia 1976; 12 (04) 343-350
• 38 Prutsky GJ, Domecq JP, Wang Z. et al. Glucose targets in pregnant women with diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2013; 98 (11) 4319-4324
• 39 de Veciana M, Major CA, Morgan MA. et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995; 333 (19) 1237-1241
• 40 Scifres CM, Mead-Harvey C, Nadeau H. et al. Intensive glycemic control in gestational diabetes mellitus: a randomized controlled clinical feasibility trial. Am J Obstet Gynecol MFM 2019; 1 (04) 100050
• 41 Scifres CM, Battarbee AN, Feghali MN. et al. Intensive glycaemic targets in overweight and obese individuals with gestational diabetes mellitus: clinical trial protocol for the iGDM study. BMJ Open 2024; 14 (02) e082126
• 42 Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343 (16) 1134-1138
• 43 Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358 (19) 2003-2015
• 44 Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin Jr DK, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol 2014; 123 (06) 1177-1184
• 45 Cesta CE, Cohen JM, Pazzagli L. et al. Antidiabetic medication use during pregnancy: an international utilization study. BMJ Open Diabetes Res Care 2019; 7 (01) e000759
• 46 Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350: h102
• 47 Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin Jr DK, Jonsson Funk M. Association of adverse pregnancy outcomes with glyburide vs insulin in women with gestational diabetes. JAMA Pediatr 2015; 169 (05) 452-458
• 48 Hebert MF, Ma X, Naraharisetti SB. et al; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85 (06) 607-614
• 49 Tarry-Adkins JL, Aiken CE, Ozanne SE. Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: a systematic review and meta-analysis. PLoS Med 2020; 17 (05) e1003126
• 50 Boggess KA, Valint A, Refuerzo JS. et al. Metformin plus insulin for preexisting diabetes or gestational diabetes in early pregnancy: The MOMPOD randomized clinical trial. JAMA 2023; 330 (22) 2182-2190
• 51 Landi SN, Radke S, Engel SM. et al. Association of long-term child growth and developmental outcomes with metformin vs insulin treatment for gestational diabetes. JAMA Pediatr 2019; 173 (02) 160-168
• 52 Dunne F, Newman C, Alvarez-Iglesias A. et al. Early metformin in gestational diabetes: a randomized clinical trial. JAMA 2023; 330 (16) 1547-1556
• 53 Harrison RK, Johnson C, Cruz M, Wong A, Davitt C, Palatnik A. Provider-based initiation and management of pharmacologic therapy for gestational diabetes mellitus. J Matern Fetal Neonatal Med 2022; 35 (23) 4478-4484
• 54 Palatnik A, Harrison RK, Thakkar MY, Walker RJ, Egede LE. Correlates of insulin selection as a first-line pharmacological treatment for gestational diabetes. Am J Perinatol 2022; 39 (01) 8-15
• 55 Venkatesh KK, Wu J, Trinh A. et al. Patient priorities, decisional comfort, and satisfaction with metformin versus insulin for the treatment of gestational diabetes mellitus. Am J Perinatol 2024; 41 (S 01): e3170-e3182
• 56 Patient-Centered Outcomes Research Institute. . Accessed on March 28, 2024 at: https://www.pcori.org/research-results/2023/decide-comparative-effectiveness-trial-oral-metformin-versus-injectable-insulin-treatment-gestational-diabetes#project_information
• 57 Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 1999; 180 (04) 903-916
• 58 Catalano PM, Tyzbir ED, Roman NM, Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol 1991; 165 (6 Pt 1): 1667-1672
• 59 Catalano PM, Tyzbir ED, Wolfe RR. et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol 1993; 264 (1 Pt 1): E60-E67
• 60 Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, Catalano P. Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes 1999; 48 (09) 1807-1814
• 61 Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM. Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. Diabetes 2008; 57 (03) 606-613
• 62 Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68 (06) 1456-1467
• 63 Kahn SE, Prigeon RL, McCulloch DK. et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42 (11) 1663-1672
• 64 Powe CE, Allard C, Battista M-C. et al. Heterogeneous contribution of insulin sensitivity and secretion defects to gestational diabetes mellitus. Diabetes Care 2016; 39 (06) 1052-1055
• 65 Benhalima K, Van Crombrugge P, Moyson C. et al. Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetologia 2019; 62 (11) 2118-2128
• 66 Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3 (03) 153-165
• 67 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87 (04) 1409-1439
• 68 Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010; 1 (1-2): 8-23
• 69 Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008; 34 (Suppl. 02) S65-S72
• 70 Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin secretory response in early pregnancy. Diabetologia 2019; 62 (08) 1445-1452
• 71 Jones DL, Petry CJ, Burling K. et al. Pregnancy glucagon-like peptide 1 predicts insulin but not glucose concentrations. Acta Diabetol 2023; 60 (12) 1635-1642
• 72 Fritsche L, Heni M, Eckstein SS. et al. Incretin hypersecretion in gestational diabetes mellitus. J Clin Endocrinol Metab 2022; 107 (06) e2425-e2430